Phase 2 N=56 A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
Glioblastoma Multiforme
Primary: Progression-free Survival Rate at 6 Months — 15.4 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=23 Fresolimumab and Radiotherapy in Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Abscopal Response Rate — 11; 12 Participants
Phase 2 N=7 Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome
HAART-induced Lipodystrophy and Metabolic Syndrome
Primary: Serum Lipid Levels — 228.8; 219.7; 113.0; 105.7 mg/dl
Phase 2 N=174 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection
Chronic Hepatitis C · Hepatitis C Virus · HCV
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks Post-treatment — 100; 97.4; 96.3; 100 percentage of participants
Phase 2 N=55 Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Hodgkin Disease
Primary: Complete Remission Rate — 73.6 percentage of participants
Phase 2 N=104 Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Overall Survival — 4.2; 8.3 months — p=0.36
Phase 2 N=16 GSK2339345 Hypertussive Challenge Study
Cough
Primary: Total Cough Count Over 8 Hours at Visits 1, 2 and 3 (Part A) — 152.7; 192.5 cough count
Phase 2 N=36 A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris
Acne Vulgaris
Primary: Safety (Number of Participants With Treatment Related Adverse Events) — 4; 1; 2; 2 Participants
Phase 2 N=37 A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus
Macular Edema · Diabetes Mellitus
Primary: Mean Change in Best Corrected Visual Acuity — 0.3; 0.33 logMAR units
Phase 2 N=36 Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level
Non-Hodgkin Lymphoma (NHL) · Cutaneous Lymphoma · Cutaneous T-cell Lymphoma (CTCL)
Primary: Overall Response Rate (ORR) — 70; 56; 79; 100 percentage
Phase 2 N=73 Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer
Lung Cancer · Adenocarcinoma
Primary: Phase I: Recommend Phase II Dose (RPDII) — 1 Recommend Phase II Dose Level
Phase 2 N=30 A Prospective Comparison of Ultrasound-Guided Percutaneous Platelet-Rich Plasma Injection
Tendinosis · Tendinitis
Primary: Pain Level and Interference With Activity — 16.8; 25.5; 15.2; 19.4 units on a scale — p=<0.0001
Phase 2 N=51 Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery
Pancreatic Cancer
Primary: One Year Survival Rate — 0.502 proportion of patients
Phase 2 N=150 ABT-436 for Alcohol Dependence
Alcohol Dependence · Alcohol Abuse · Alcohol Use Disorders
Primary: Weekly Percentage of Heaving Drinking Days — 37.6; 31.3 weekly percentage of heavy drinking days
Phase 2 N=32 Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer
Lung Cancer
Primary: Number of Participants Showing Immunologic Response to Vaccine Within Six Months of Immunization — 22 participants with immunological response